(FDMT) 4D Molecular Therapeutics - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 462m USD | Total Return: 127% in 12m
Avg Turnover: 6.32M
Qual. Beats: 0
Rev. Trend: -12.8%
Qual. Beats: 0
Warnings
Share dilution 22.1% YoY
Volatile
Tailwinds
No distinct edge detected
4D Molecular Therapeutics (FDMT) is a late-stage biotechnology firm specializing in gene therapy via its proprietary Therapeutic Vector Evolution platform. The company utilizes directed evolution to engineer synthetic adeno-associated virus (AAV) vectors designed to deliver genetic payloads more efficiently than naturally occurring viruses. Its primary clinical focus is 4D-150, an intravitreal treatment for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema.
The company operates within the high-risk, high-reward gene therapy sector, where business models typically rely on heavy R&D investment and strategic partnerships to navigate multi-phase clinical trials. FDMT currently maintains a collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. Beyond ophthalmology, the pipeline includes 4D-710 for cystic fibrosis and preclinical candidates targeting geographic atrophy and lung disease.
To better understand how these clinical milestones might affect long-term valuation, consider reviewing the latest technical data on ValueRay. 4D Molecular Therapeutics was founded in 2013 and is headquartered in Emeryville, California.
- Clinical trial results for 4D-150 determine competitive viability in wet AMD market
- FDA design designations accelerate regulatory timeline for lead gene therapy candidates
- Cash runway and burn rate dictate timing of future equity dilution
- Strategic partnership milestones with Otsuka Pharmaceutical influence non-dilutive revenue streams
- Manufacturing scalability of proprietary AAV vectors impacts long-term gross margin potential
| Net Income: -160.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 5.08 > 1.0 |
| NWC/Revenue: 410.2% < 20% (prev 1.33m%; Δ -1.33m% < -1%) |
| CFO/TA -0.25 > 3% & CFO -129.4m > Net Income -160.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.1m) vs 12m ago 22.10% < -2% |
| Gross Margin: -12.45% > 18% (prev -490k%; Δ 490k% > 0.5%) |
| Asset Turnover: 17.16% > 50% (prev 0.00%; Δ 17.15% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.71 (Total Current Assets 405.4m - Total Current Liabilities 43.4m) / Total Assets 512.9m |
| B: -1.53 (Retained Earnings -785.1m / Total Assets 512.9m) |
| C: -0.33 (EBIT TTM -169.9m / Avg Total Assets 514.3m) |
| D: 7.40 (Book Value of Equity 451.8m / Total Liabilities 61.1m) |
| Altman-Z'' = 5.19 = AAA |
As of June 18, 2026, the stock is trading at USD 9.42 with a total of 877,154 shares traded.
Over the past week, the price has changed by +8.03%,
over one month by +12.61%,
over three months by +9.41% and
over the past year by +126.99%.
4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.
- StrongBuy: 5
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 28.2 | 199.6% |
P/S = 5.2311
P/B = 1.0216
Revenue TTM = 88.2m USD
EBIT TTM = -169.9m USD
EBITDA TTM = -169.6m USD
Long Term Debt = 9.56m USD (estimated: total debt 20.5m - short term 11.0m)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 20.5m USD (from shortLongTermDebtTotal, last quarter) (leases 20.5m already included)
Net Debt = -370.4m USD (calculated: Debt 20.5m - CCE 390.9m)
Enterprise Value = 91.2m USD (461.6m + Debt 20.5m - CCE 390.9m)
Interest Coverage Ratio = unknown (Ebit TTM -169.9m / Interest Expense TTM 0.0)
EV/FCF = -0.70x (Enterprise Value 91.2m / FCF TTM -130.1m)
FCF Yield = -142.5% (FCF TTM -130.1m / Enterprise Value 91.2m)
FCF Margin = -147.4% (FCF TTM -130.1m / Revenue TTM 88.2m)
Net Margin = -182.3% (Net Income TTM -160.9m / Revenue TTM 88.2m)
Gross Margin = -12.45% ((Revenue TTM 88.2m - Cost of Revenue TTM 99.2m) / Revenue TTM)
Gross Margin QoQ = 32.56% (prev none%)
Tobins Q-Ratio = 0.18 (Enterprise Value 91.2m / Total Assets 512.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 20.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -134.2m (EBIT -169.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.34 (Total Current Assets 405.4m / Total Current Liabilities 43.4m)
Debt / Equity = 0.05 (Debt 20.5m / totalStockholderEquity, last quarter 451.8m)
Debt / EBITDA = 2.18 (negative EBITDA) (Net Debt -370.4m / EBITDA -169.6m)
Debt / FCF = 2.85 (negative FCF - burning cash) (Net Debt -370.4m / FCF TTM -130.1m)
Total Stockholder Equity = 436.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.28% (Net Income -160.9m / Total Assets 512.9m)
RoE = -36.83% (Net Income TTM -160.9m / Total Stockholder Equity 436.8m)
RoCE = -38.06% (EBIT -169.9m / Capital Employed (Equity 436.8m + L.T.Debt 9.56m))
RoIC = -28.19% (negative operating profit) (NOPAT -134.2m / Invested Capital 476.1m)
WACC = 9.56% (E(461.6m)/V(482.1m) * Re(9.99%) + D(20.5m)/V(482.1m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 27.89%
[DCF] Fair Price = unknown (Cash Flow -130.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: -12.83 | Revenue CAGR: -39.03% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.01 | Chg30d=-2.73% | Revisions=-17% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-1.01 | Chg30d=-3.32% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.92 | Chg30d=-2.46% | Revisions=+0% | GrowthEPS=-62.0% | GrowthRev=-86.4%
EPS next Year (2027-12-31): EPS=-3.72 | Chg30d=+3.40% | Revisions=-9% | GrowthEPS=+5.0% | GrowthRev=+50.9%
[Analyst] Revisions Ratio: -17%